10 Trending AI Health Stocks

3. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 80

Johnson & Johnson (NYSE:JNJ) has integrated AI into its MedTech and pharmaceutical divisions, particularly in surgical robotics and drug discovery. Ethicon, a subsidiary of J&J, uses AI in surgical planning and execution, improving precision and patient outcomes. AI tools are also aiding J&J in advancing drug discovery, particularly in oncology and immunology, where AI accelerates the identification of new therapies.

Financially, AI-driven innovations have positively impacted J&J’s performance. In 2023, the company’s total sales rose to $85.2 billion, a 6.5% year-over-year increase. The MedTech segment grew by 12.4%, reflecting strong demand for AI-enhanced surgical tools. In 2024, Johnson & Johnson (NYSE:JNJ) expects revenues between $89.2 billion and $89.6 billion, driven by growth in its MedTech and Innovative Medicine segments, which benefit from AI advancements in surgery and drug development.